Zur Kurzanzeige

2021-04-30Zeitschriftenartikel
Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations
dc.contributor.authorDuwe, Susanne
dc.contributor.authorSchmidt, Barbara
dc.contributor.authorGärtner, Barbara C.
dc.contributor.authorTimm, Jörg
dc.contributor.authorAdams, Ortwin
dc.contributor.authorFickenscher, Helmut
dc.contributor.authorSchmidtke, Michaela
dc.date.accessioned2024-06-10T11:33:49Z
dc.date.available2024-06-10T11:33:49Z
dc.date.issued2021-04-30none
dc.identifier.other10.3205/id000071
dc.identifier.urihttp://edoc.rki.de/176904/11699
dc.description.abstractInfluenza viruses of types A and B attack 5–10% of adults and 20–30% of children, thereby causing millions of acute respiratory infections in Germany annually. A significant number of these infections are associated with complications such as pneumonia and bacterial superinfections that need hospitalization and might lead to death. In addition to vaccines, drugs were developed that might support influenza prevention and that can be used to treat influenza patients. The timely application of anti-influenza drugs can inhibit virus replication, help reduce and shorten the symptoms, and prevent death as well as virus transmission. This review concisely describes the mechanism of action, the potential for prophylactic and therapeutic use, and the knowledge on resistance of anti-influenza drugs approved today. However, the main aim is to give an overview on the recommendations available in Germany for the proper use of these drugs. In doing so, the recommendations published in statements and guidelines of medical societies as well as the German influenza pandemic preparedness plan are summarized with the consideration of specific circumstances and groups of patients.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectinfectioneng
dc.subjectneuraminidaseeng
dc.subjectbaloxavireng
dc.subjectpolymeraseeng
dc.subjectresistanceeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleProphylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendationsnone
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/11699-7
dc.type.versionpublishedVersionnone
local.edoc.container-titleGMS Infectious Diseasesnone
local.edoc.container-issn2195-8831none
local.edoc.pages12none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.egms.de/dynamic/en/journals/id/index.htmnone
local.edoc.container-publisher-nameGerman Medical Science gGmbHnone
local.edoc.container-volume9none
local.edoc.container-reportyear2021none
dc.description.versionPeer Reviewednone

Zur Kurzanzeige